Omnicell, Inc. (NASDAQ:OMCL) Shares Sold by Jacobs Levy Equity Management Inc.

Jacobs Levy Equity Management Inc. trimmed its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL) by 84.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 73,506 shares of the company’s stock after selling 391,313 shares during the quarter. Jacobs Levy Equity Management Inc. owned approximately 0.16% of Omnicell worth $2,149,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. EntryPoint Capital LLC increased its position in shares of Omnicell by 121.2% during the first quarter. EntryPoint Capital LLC now owns 2,455 shares of the company’s stock worth $72,000 after purchasing an additional 1,345 shares in the last quarter. Benjamin Edwards Inc. boosted its stake in Omnicell by 36.4% during the first quarter. Benjamin Edwards Inc. now owns 3,253 shares of the company’s stock worth $95,000 after buying an additional 868 shares during the last quarter. Strs Ohio increased its stake in shares of Omnicell by 28.2% in the 4th quarter. Strs Ohio now owns 5,000 shares of the company’s stock worth $188,000 after acquiring an additional 1,100 shares during the last quarter. Entropy Technologies LP purchased a new stake in shares of Omnicell in the first quarter valued at about $227,000. Finally, ProShare Advisors LLC boosted its holdings in Omnicell by 7.4% in the 1st quarter. ProShare Advisors LLC now owns 9,076 shares of the company’s stock valued at $265,000 after purchasing an additional 626 shares during the last quarter. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Omnicell Stock Performance

Shares of Omnicell stock opened at $29.21 on Thursday. The firm has a market capitalization of $1.34 billion, a P/E ratio of -63.50, a P/E/G ratio of 82.28 and a beta of 0.80. The company has a quick ratio of 2.13, a current ratio of 2.38 and a debt-to-equity ratio of 0.48. Omnicell, Inc. has a 52 week low of $25.12 and a 52 week high of $66.65. The firm’s 50 day moving average is $28.56 and its two-hundred day moving average is $29.00.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, May 2nd. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.17. Omnicell had a positive return on equity of 2.41% and a negative net margin of 1.91%. The company had revenue of $246.15 million for the quarter, compared to analyst estimates of $235.70 million. Research analysts forecast that Omnicell, Inc. will post 0.25 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Benchmark reaffirmed a “buy” rating and set a $38.00 price target on shares of Omnicell in a research report on Monday, July 15th. StockNews.com downgraded shares of Omnicell from a “buy” rating to a “hold” rating in a report on Tuesday, July 16th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $42.20.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.